Open-label, uncontrolled, 6-week clinical trial of beraprost in patients with chronic occlusive arterial disease

Current Therapeutic Research - Clinical and Experimental

Volumn 59, Issue 9, 1998, Pages 645-653

  Suh, Bo Yang ^a   Kwun, Koing Bo ^a   Kwun, Tae Weon ^b   Kim, Suk Koo ^b   Yoon, Jun O ^b   Yamamoto, Minoru ^c  

^a Yeungnam University College of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c ASTELLAS PHARMA INC   (Japan)

Author keywords

Beraprost; Ischemia; Occlusive arterial disease; Ulceration

Indexed keywords

BERAPROST;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERANCE; DRUG USE; FEMALE; HUMAN; LIMB BLOOD FLOW; LIMB ISCHEMIA; MALE; ORAL DRUG ADMINISTRATION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL;

EID: 7344222581     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(98)85062-5     Document Type: Article

References (20)

1. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ. 1994;308:159-168.
2. Takeo S. Pharmacodynamics and clinical studies with beraprost sodium, a drug for peripheral vascular disease. Cardiovasc Drug Rev. 1993;10:392-403.
3. Sinzinger H, Fitscha P, Kritz H. Antimitotic actions of vasodilatory prostaglandins -clinical aspects. Agents Actions. 1997;48(Suppl):92-106.
4. Fujioka K, Essato K, Zempo N. Effect of elastase on primary graft patency after femoral popliteal arterial bypass for arteriosclerosis obliterans: A randomized controlled study. Int Surg. 1997;82:94-97.
5. Katsumura T, Mishima Y, Kamiya K, et al. Therapeutic effect of ticlopidine, a new inhibitor of platelet aggregation, on chronic arterial occlusive disease: A double blind study with inactive placebo. Cardioangiology. 1980;7:396-406.
6. Uchikawa T, Murakami T, Furukawa H. Effects of the anti-platelet agent cilostazol on peripheral vascular disease in patients with diabetes mellitus. Arzneim-Forsch / Drug Res. 1992;42:322-324.
7. Moncada S, Gryglewski S, Bunting S, et al. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature. 1976;263:663-665.
8. 2 on platelet aggregation in different species. Prostaglandins. 1978;16:373-388.
9. Waldman HM, Alter I, Kot PA, et al. Effect of lung transit on systemic depressor responses to arachidonic acid and prostacyclin in dogs. J Pharmacol Exp Ther. 1978;204:289-293.
10. El-Tahir KEH, Williams KI, Betteridge DJ. Differences in the stability of prostacyclin in human, rabbit and rat plasma. Prostaglandins Leukot Med. 1983;10:109-114.
11. Ohno K, Nagase H, Matsumoto K, et al. Stereoselective synthesis of 5,6,7-trinor-4,8-inter-m-phenylene-PGI2 derivatives and their inhibitory activities to human platelet aggregation. Adv Prostaglandin Thromboxane Leukot Res. 1985;15:279-281.
12. Sim AK, McCraw AP, Cleland ME, et al. Effect of a stable prostacyclin analogue on platelet function and experimentally induced thrombosis in the microcirculation. Arzneim-Forsch / Drug Res. 1985;35:1816-1818.
13. Kajikawa N, Nogimori K, Murata T, et al. Specific binding of the new stable epoprostenol analogue beraprost sodium to prostacyclin receptors on human and rat platelets. Arzneim-Forsch / Drug Res. 1989;39:495-499.
14. Umetsu T, Murata T, Nishio S. Studies on the antiplatelet effect of the stable epoprostenol analogue beraprost sodium and its mechanism of action in rats. Arzneim-Forsch / Drug Res. 1989;39:68-73.
15. Nishio S, Matsuura H, Kanai N, et al. The in vitro and ex vivo antiplatelet effect of TRK-100, a stable prostacyclin analog, in several species. Jpn J Pharmacol. 1988;47:1-10.
16. 2 analogue. Br J Pharmacol. 1986;89:703-711.
17. Murai T, Muraoka K, Saga K, et al. Effect of beraprost sodium on peripheral circulation insufficiency in rats and rabbits. Arzneim-Forsch / Drug Res. 1989;39:856-859.
18. Sakai A, Yajima M, Nishio S. Cytoprotective effect of TRK-100, a prostacyclin analogue, against chemical injuries in cultured human vascular endothelial cells. Life Sci. 1990;47:711-719.
19. Kainoh M, Maruyama I, Nishio S, et al. Enhancement by beraprost sodium, a stable analogue of prostacyclin, in thrombomodulin expression on membrane surface of cultured vascular endothelial cells via increase in cyclic AMP level. Biochem Pharmacol. 1991;41:1135-1140.
20. 2 derivative, on chronic arterial occlusive diseases. Clin Res. 1990;67:575-584.